NICEATM
This article was originally published in The Rose Sheet
Executive Summary
National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods announces availability of two updated standardized in vitro cytotoxicity test method protocols for estimating acute oral systemic toxicity in rodents in Oct. 19 Federal Register notice. Protocols were recommended by Interagency Coordinating Committee on the Validation of Alternative Methods for determining starting doses for in vivo acute oral systemic tests to reduce the number of animals necessary in testing. NICEATM also requests data on chemicals and products tested for acute oral systemic toxicity and in vitro cytotoxicity using the standardized test method protocols. Data will be used to determine usefulness of cytotoxicity methods for estimating in vivo acute oral toxicity and investigate other methods to improve accuracy of in vitro assessments of acute systemic toxicity. Agency currently is accepting comments...
You may also be interested in...
NICEATM request
National Toxicology Program Interagency Center on Evaluation of Alternative Toxicological Methods requests nominations for scientists to sit on expert panel that will evaluate the validation status of two in vitro cytotoxicity assays for estimating in vivo acute oral toxicity in March 22 Federal Register 1notice. ICCVAM would consider the panel's conclusions in developing test method recommendations and performance standards, agency adds. Nominations should be sent to NICEATM Director William Stokes by May 6. NICEATM also is requesting data on standard in vivo acute oral toxicity and in vitro cytotoxicity tests. Agency announced the availability of the test protocols in October (2The Rose Sheet" Oct. 25, 2004, In Brief)...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.